RA TNF Antagonists

Clifton Bingham, M.D. - Jon Giles, M.D.

Abstract 676: A Difference in Effectiveness Between Infliximab, Etanercept and Adalimumab in Patients with Rheumatoid Arthritis

Abstract 1235: Abilities to Develop Protective Antibodies to Pneumococcal and Influenza Vaccine are Maintained in Rheumatoid Arthritis (RA) Patients Treated with Adalimumab (Humira®)

Abstract 1311: Delay in Imaging Versus Clinical Response Provides Rationale for Prolonged Treatment with Anti-TNF in Early Rheumatoid Arthritis

Abstract 2123: One-Year Results of Golimumab Compared With Placebo in Patients With Active RA Despite Treatment With Methotrexate: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

• Rheumatoid Arthritis
• Treatment Strategies
• TNF Antagonists
• B-Cell Depletion
• Other Agents
• OA Clinical Aspects
• Juvenile RA / Pediatric Rheumatology
• Systemic Lupus Erythematosus
• Vasculitis
• Scleroderma
• Fibromyalgia
• Spondyloarthropathies
• Myositis
• Pregnancy in AutoImmune Disease
• Non-Pharmacologic Management
• Basic Science
• Epidemiology
• Psychosocial